MX2019009482A - FORMAS FARMACEUTICAS DEL ACIDO 18ß-GLICIRRETINICO. - Google Patents

FORMAS FARMACEUTICAS DEL ACIDO 18ß-GLICIRRETINICO.

Info

Publication number
MX2019009482A
MX2019009482A MX2019009482A MX2019009482A MX2019009482A MX 2019009482 A MX2019009482 A MX 2019009482A MX 2019009482 A MX2019009482 A MX 2019009482A MX 2019009482 A MX2019009482 A MX 2019009482A MX 2019009482 A MX2019009482 A MX 2019009482A
Authority
MX
Mexico
Prior art keywords
pharmaceutical forms
glicirretinico
acid
particle size
application
Prior art date
Application number
MX2019009482A
Other languages
English (en)
Inventor
Hernandez Ulises Zendejas
Original Assignee
Proyectos Atso S A P I De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyectos Atso S A P I De C V filed Critical Proyectos Atso S A P I De C V
Priority to MX2019009482A priority Critical patent/MX2019009482A/es
Priority to CA3147206A priority patent/CA3147206A1/en
Priority to BR112022002176A priority patent/BR112022002176A2/pt
Priority to US17/633,823 priority patent/US20220296544A1/en
Priority to CN202080068420.7A priority patent/CN114450001A/zh
Priority to PCT/MX2020/050025 priority patent/WO2021025550A1/es
Priority to EP20849613.3A priority patent/EP4023219A4/en
Publication of MX2019009482A publication Critical patent/MX2019009482A/es
Priority to ZA2022/02125A priority patent/ZA202202125B/en
Priority to CONC2022/0002493A priority patent/CO2022002493A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a formas farmacéuticas que potencializan la biodisponibilidad del 18B-AG, al tener una alta permeación en el sitio o zona de aplicación principalmente por efecto de su reducido tamaño de partícula, la alta concentración del compuesto activo, su composición de excipientes, micelas con composición estructural y polaridad específicas. Las formas farmacéuticas de la presente invención exhiben valores específicos de tamaño de partícula, permeabilidad, coeficiente de difusión y polidispersión específicas que ayudan a la invención a proporcionar sus ventajas técnicas. La presente invención describe también los usos terapéuticos de las formas farmacéuticas descritas, principalmente las soluciones, emulsiones y nanoemulsiones gelificadas, pensadas para su aplicación en la zona vaginal y del cérvix, para el tratamiento de enfermedades relacionas con el virus de papiloma humano, como infecciones, lesiones y cáncer cérvico uterino.
MX2019009482A 2019-08-08 2019-08-08 FORMAS FARMACEUTICAS DEL ACIDO 18ß-GLICIRRETINICO. MX2019009482A (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MX2019009482A MX2019009482A (es) 2019-08-08 2019-08-08 FORMAS FARMACEUTICAS DEL ACIDO 18ß-GLICIRRETINICO.
CA3147206A CA3147206A1 (en) 2019-08-08 2020-08-07 Nanoemulsion of 18.beta.-glycyrrhetinic acid
BR112022002176A BR112022002176A2 (pt) 2019-08-08 2020-08-07 Nanoemulsão de ácido 18ss-glicirretínico.
US17/633,823 US20220296544A1 (en) 2019-08-08 2020-08-07 Nanoemulsion of 18beta-glycyrrhetinic acid
CN202080068420.7A CN114450001A (zh) 2019-08-08 2020-08-07 18β-甘草次酸的纳米乳液
PCT/MX2020/050025 WO2021025550A1 (es) 2019-08-08 2020-08-07 Nanoemulsion de ácido 18p-glicirretínico
EP20849613.3A EP4023219A4 (en) 2019-08-08 2020-08-07 PHARMACEUTICAL FORMS OF 18BETA-GLYCYRRHETINIC ACID
ZA2022/02125A ZA202202125B (en) 2019-08-08 2022-02-18 Nanoemulsion of 18 beta-glycyrrhetinic acid
CONC2022/0002493A CO2022002493A2 (es) 2019-08-08 2022-03-01 Nanoemulsion de ácido 18p-glicirretínico

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2019009482A MX2019009482A (es) 2019-08-08 2019-08-08 FORMAS FARMACEUTICAS DEL ACIDO 18ß-GLICIRRETINICO.

Publications (1)

Publication Number Publication Date
MX2019009482A true MX2019009482A (es) 2021-02-09

Family

ID=74503526

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009482A MX2019009482A (es) 2019-08-08 2019-08-08 FORMAS FARMACEUTICAS DEL ACIDO 18ß-GLICIRRETINICO.

Country Status (9)

Country Link
US (1) US20220296544A1 (es)
EP (1) EP4023219A4 (es)
CN (1) CN114450001A (es)
BR (1) BR112022002176A2 (es)
CA (1) CA3147206A1 (es)
CO (1) CO2022002493A2 (es)
MX (1) MX2019009482A (es)
WO (1) WO2021025550A1 (es)
ZA (1) ZA202202125B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023159476A1 (en) 2022-02-25 2023-08-31 L'oreal Composition for caring for keratin materials

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2072014B (en) * 1980-03-08 1984-02-15 Kanebo Ltd Cosmetics containing 18-glycyrrhizins
LU86396A1 (fr) * 1986-04-18 1986-09-02 Pharma Roche Posay Lab Compositions pour le traitement de la calvitie et des alopecies
MX351117B (es) * 2011-02-25 2017-10-03 Desarrollos Vph S A De C V Formulacion de la sal acido glicirricinico en gel termorreversible y acido tricloroacetico para su aplicacion en el tracto genital de mujeres y varones con lesiones causadas por el virus del papiloma humano y cancer en los mismos.
RU2493852C1 (ru) * 2012-04-12 2013-09-27 Леонид Леонидович Клопотенко Композиция, содержащая фермент дезоксирибонуклеазу и/или стеарилглицирретинат или глицирризиновую кислоту или ее соли: глицирризинат аммония, или дикалия, или тринатрия
CN105342987A (zh) * 2015-12-04 2016-02-24 亚飞(上海)生物医药科技有限公司 一种凝胶及其制备方法和应用
ITUB20159218A1 (it) * 2015-12-21 2017-06-21 Valitudo Pharma Srls Composizione, per uso topico, utile per favorire la cicatrizzazione di lesioni sulla pelle.
MX2017010806A (es) * 2017-08-22 2018-01-18 Atso Corp Affairs S A De C V Formulacion de acido 18-beta-glicirretinico en combinacion con revesterol y metformina, usos y metodo de fabricacion.

Also Published As

Publication number Publication date
BR112022002176A2 (pt) 2022-05-03
CN114450001A (zh) 2022-05-06
EP4023219A4 (en) 2023-04-26
US20220296544A1 (en) 2022-09-22
CA3147206A1 (en) 2021-02-11
EP4023219A1 (en) 2022-07-06
WO2021025550A1 (es) 2021-02-11
ZA202202125B (en) 2023-11-29
CO2022002493A2 (es) 2022-04-29

Similar Documents

Publication Publication Date Title
CY1122181T1 (el) Φαρμακοτεχνικη μορφη αντισωματος
AU2017265011B2 (en) Methods of administering high concentrations of nitric oxide
WO2016037154A8 (en) Recombinant hiv-1 envelope proteins and their use
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
RU2017134443A (ru) Способ лечения с применением традипитанта
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
MA35130B1 (fr) Composition comprenant de l'aflibercept, de l'acide folinique, du 5-fluoro-uracile (5-fu) et de l'irinocetan (folfiri)
MX2019009777A (es) Sistemas y metodos para la fabricacion de tabletas, que incluyen tabletas farmaceuticas.
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA202190115A1 (ru) Пленочные составы, содержащие дексмедетомидин, и способы их получения
CY1121660T1 (el) Φαρμακευτικη συνθεση για τη θεραπεια των hiv λοιμωξεων
WO2019046568A8 (en) High concentration dosage forms of pridopidine
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
MX2019009482A (es) FORMAS FARMACEUTICAS DEL ACIDO 18ß-GLICIRRETINICO.
EA201390950A1 (ru) Гомогенные фармацевтические пероральные лекарственные формы, содержащие лерканидипин и эналаприл или их фармацетически приемлемые соли совместно с органической кислотой
EA201590474A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
EA201791458A1 (ru) Фармацевтическая композиция для лечения заболеваний желудочно-кишечного тракта
MX2017015699A (es) Composiciones de acido diclofenaco.
WO2015011653A9 (en) pH RESPONSIVE ORAL POLYMERIC PHARMACEUTICAL DOSAGE FORM
TR201721700A2 (tr) Saksagli̇pti̇ni̇n ağizda dağilan formülasyonlari
MX370184B (es) Composición farmacéutica que comprende fingolimod.
MX2018005345A (es) Composiciones farmaceuticas de dimetil fumarato.
PE20220932A1 (es) Composicion farmaceutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso